Arvinas Inc ARVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arvinas to Participate in Upcoming Investor Conferences
-
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
-
Milestone Pharmaceuticals Refreshes Board of Directors
-
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.73
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 445
- Website
- https://www.arvinas.com
Comparables
Valuation
|
Metric
|
ARVN
|
MGNX
|
EXEL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.02 |
Price/Book Value | 2.83 | 3.46 | 3.49 |
Price/Sales | 11.73 | 5.03 | 3.97 |
Price/Cash Flow | — | — | 16.25 |
Price/Earnings
ARVN
MGNX
EXEL
Financial Strength
|
Metric
|
ARVN
|
MGNX
|
EXEL
|
|---|---|---|---|
Quick Ratio | 3.57 | 2.53 | 4.05 |
Current Ratio | 3.62 | 2.71 | 4.27 |
Interest Coverage | — | −128.87 | — |
Quick Ratio
ARVN
MGNX
EXEL
Profitability
|
Metric
|
ARVN
|
MGNX
|
EXEL
|
|---|---|---|---|
Return on Assets (Normalized) | −22.33% | −59.21% | 14.82% |
Return on Equity (Normalized) | −47.53% | −120.96% | 19.05% |
Return on Invested Capital (Normalized) | −54.26% | −102.88% | 14.99% |
Return on Assets
ARVN
MGNX
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kvjgflsqd | Fkmcz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wvtlynvdc | Hbwsck | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bcqrwvlly | Wjymbm | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cxvsqkwd | Zvbljx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Ffgpnnqlc | Tnbf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cbqwygsnj | Qdvv | $28.1 Bil | |||
| Moderna Inc
MRNA
| Czsrzkp | Tcqmn | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pbbpdyvrm | Wjl | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jxczdwqq | Djckkr | $13.4 Bil | |||
| Incyte Corp
INCY
| Lnrzpdnds | Trfmr | $12.7 Bil |
United States